Nature's Bioceuticals Finalizes the Purchase of Chronic Kidney Disease Formula

CAPE CORAL, Fla., Nov. 7, 2011 /PRNewswire/ -- Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. (MILV) announced that it has executed the formal closing documents and acquired the chronic kidney disease (CKD) formula. This formula was developed to restore proper kidney function.

Chronic kidney disease (CKD) is a growing health problem in the United States. A report by the Centers for Disease Control (CDC) determined that 16.8% of all adults above the age of 20 years have chronic kidney disease. The prevalence of chronic kidney disease has increased by 16% from the previous decade. The increasing incidence of diabetes mellitus, hypertension (high blood pressure), obesity, and an aging population have contributed to this increase in kidney disease. Kidney disease raises the risk of early death, heart attack, stroke, and high blood pressure. CKD causes anemia, bone disease and malnutrition and can lead to kidney failure, which requires ongoing dialysis or a kidney transplant to maintain life. According to the National Institute of Health's U.S. Renal Data System, over 100,000 Americans started dialysis in 2005 while a total of over 485,000 received ongoing dialysis treatment or a kidney transplant, at a cost of $32 billion. The NIH estimates that by 2020 nearly 785,000 people will be receiving treatment for kidney failure, costing an estimated $53.6 billion. The healthcare costs for one person needing dialysis are between $150,000 – $200,000 per year, with annual global dialysis costs exceeding $1 trillion this decade.

Robert deZanger, CEO of Natures Bioceuticals reiterates "We are confident that this product will make a meaningful contribution to one of the most overlooked diseases known to man. There are over 26 million Americans with CKD. The problem is most people with CKD aren't even aware they have the disease. Studies show that 4 out of 5 people with advanced CKD (i.e. loss of over 50% of kidney function) do not know they have the disease. Unless tested, diagnosed and dialysis or a transplant is available, many of these people only become unwell after severe kidney failure, when death is imminent. People who have taken our formula have shown substantial increases in kidney function in very short time frames. One positive side effect that has been noted is that the product seems to also shrink enlarged prostrate glands. This could be a second market for the product.  We now intend to initiate the filing of the patent(s) and also make arrangements to begin clinical trials to document the amazing results obtained to this point. The revenues this product could produce for the company should be substantial. Capturing a very small percentage of the market could produce tens of millions of dollars for the company."

About Nature's Bioceuticals:

Nature's Bioceuticals develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. These medicines are all natural and derived from botanicals and mineral bases. Nature's Bioceuticals strives to provide high quality natural medicines that are as effective, if not more effective, than synthetic drugs and more importantly do not have the negative side effects usually associated with many of today's prescribed drugs.

Nature's line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA, or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, commonly referred to as "DSHEA"

In addition to historical information, this release contains forward-looking statements.

Mistral Ventures, Inc. and/or Nature's Bioceuticals may, from time to time, make written or oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements encompass Mistral Ventures, Inc. and/or Nature's Bioceuticals beliefs, expectations, hopes, or intentions regarding future events. Words such as "expects," "intends," "believes," "anticipates," "should," "likely," and similar expressions identify forward-looking statements. All forward-looking statements included in this release are made as of the date hereof and are based on information available to the Company as of such date. Neither Mistral Ventures, Inc. nor Nature's Bioceuticals assume any obligation to update any forward-looking statement.

Actual results will vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of reasons, including, among others: further reviews of the Company's financial statements by the Company and its Audit Committee; modification of the Company's accounting practices; foreign business risks; industry cyclicality; fluctuations in customer demand and order pattern; changes in pricing and general economic conditions; as well as other risks that may be delineated from time to time or filed with the SEC.

Media Contact:
Financial Insights
Phone Number: 888 656 3509
E-mail: [email protected]
www.naturesbioceuticals.com

SOURCE Mistral Ventures Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED